LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 3 | A24 | 72 | hr | 2543 | 5092 | 5760 | 0.8839 | 0.8013 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 2543 | 4747 | 5734 | 0.8278 | 0.7024 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 2543 | 4666 | 5761 | 0.8099 | 0.6726 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 2543 | 5184 | 5760 | 0.8999 | 0.8289 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 2543 | 4976 | 5734 | 0.8677 | 0.7721 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 2543 | 4690 | 5761 | 0.8140 | 0.6799 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 2543 | 4886 | 5760 | 0.8481 | 0.7393 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 2543 | 4560 | 5734 | 0.7952 | 0.6450 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 2543 | 4443 | 5761 | 0.7712 | 0.6046 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 2543 | 5228 | 5760 | 0.9075 | 0.8420 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 2543 | 4002 | 5734 | 0.6979 | 0.4718 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 2543 | 3691 | 5761 | 0.6406 | 0.3712 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 2543 | 4014 | 5760 | 0.6968 | 0.4723 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 2543 | 1681 | 5734 | 0.2931 | -0.2975 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 2543 | 1738 | 5761 | 0.3017 | -0.2759 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 2543 | 1914 | 5760 | 0.3322 | -0.2142 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 2543 | 5595 | 5258 | 1.0639 | 1.1218 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 2543 | 5233 | 5438 | 0.9623 | 0.9311 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 2543 | 5497 | 5557 | 0.9891 | 0.9807 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 2543 | 5070 | 5258 | 0.9641 | 0.9314 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 2543 | 5068 | 5438 | 0.9319 | 0.8755 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 2543 | 5494 | 5557 | 0.9886 | 0.9798 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 2543 | 5161 | 5258 | 0.9814 | 0.9645 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 2543 | 4928 | 5438 | 0.9062 | 0.8281 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 3 | D04 | 72 | hr | 2543 | 5061 | 5557 | 0.9107 | 0.8408 |